Author

María Dolores Martín-Arranz

IMPACT OF THE HLA-DQA1*05 ALLELE ON LOSS OF RESPONSE AND PRESENCE OF ANTI-DRUG ANTIBODIES TO USTEKINUMAB IN CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS
IMPACT OF THE HLA-DQA1*05 ALLELE ON LOSS OF RESPONSE AND PRESENCE OF ANTI-DRUG ANTIBODIES TO USTEKINUMAB IN CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS

María Dolores Martín-Arranz  et al.

USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

María Dolores Martín-Arranz  et al.

LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT
LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT

María Dolores Martín-Arranz  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

María Dolores Martín-Arranz  et al.

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

María Dolores Martín-Arranz  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

María Dolores Martín-Arranz  et al.

LOW PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS SYNDROME: A NOT SO RARE CAUSE OF BILIARY DISEASE
LOW PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS SYNDROME: A NOT SO RARE CAUSE OF BILIARY DISEASE

María Dolores Martín-Arranz  et al.

UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE
UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE

María Dolores Martín-Arranz  et al.

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

María Dolores Martín-Arranz  et al.

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

María Dolores Martín-Arranz  et al.

CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

María Dolores Martín-Arranz  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

María Dolores Martín-Arranz  et al.

THE IMPORTANCE OF ANTITNF LEVELS DURING THE INDUCTION IN PERIANAL CROHN´S DISEASE
THE IMPORTANCE OF ANTITNF LEVELS DURING THE INDUCTION IN PERIANAL CROHN´S DISEASE

María Dolores Martín-Arranz  et al.

LUPUS ENTERITIS AS DIFFERENTIAL DIAGNOSIS FOR CHRONIC DIARRHEA
LUPUS ENTERITIS AS DIFFERENTIAL DIAGNOSIS FOR CHRONIC DIARRHEA

María Dolores Martín-Arranz  et al.

ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN´S DISEASE
ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN´S DISEASE

María Dolores Martín-Arranz  et al.

INCIDENCE AND EVOLUTION OF INFLAMMATORY JOINT PATHOLOGY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE IN PATIENTS ON VEDOLIZUMAB/USTEKINUMAB TREATMENT
INCIDENCE AND EVOLUTION OF INFLAMMATORY JOINT PATHOLOGY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE IN PATIENTS ON VEDOLIZUMAB/USTEKINUMAB TREATMENT

María Dolores Martín-Arranz  et al.

CORRELATION BETWEEN ULTRASOUND AND ENDOSCOPIC SCORES FOR ASSESSING INFLAMMATORY ACTIVITY IN CROHN'S DISEASE
CORRELATION BETWEEN ULTRASOUND AND ENDOSCOPIC SCORES FOR ASSESSING INFLAMMATORY ACTIVITY IN CROHN'S DISEASE

María Dolores Martín-Arranz  et al.

ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN´S DISEASE
ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN´S DISEASE

María Dolores Martín-Arranz  et al.

COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María Dolores Martín-Arranz  et al.

CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE
CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE

María Dolores Martín-Arranz  et al.

Item 1 - 20 / 39
1
2